Wilms' Tumor Protein 1 (WT1) Peptide Vaccination in AML Patients: Predominant TCR CDR3β Sequence Associated with Remission in One Patient is Detectable in Other Vaccinated Patients

Overview

Journal Cancer Immunol Immunother

Specialties Allergy & Immunology
Oncology
Pharmacology

Date 2011 Sep 8

PMID 21898091

Citations 9

Authors

Sebastian Ochsenreither

Alberto Fusi

Anne Geikowski

David Stather

Antonia Busse

Andrea Stroux

Anne Letsch

Ulrich Keilholz

Affiliations

Soon will be listed here.

Abstract

Background: Clinically effective T-cell responses can be elicited by single peptide vaccination with Wilms' tumor 1 (WT1) epitope 126-134 in patients with acute myeloid leukemia (AML). We recently showed that a predominant T-cell receptor (TCR) β chain was associated with vaccine-induced complete remission in an AML patient (patient 1). In this study, we address the question of whether this predominant clone or the accompanying Vβ11 restriction could be found in other AML patients vaccinated with the same WT1 peptide.

Materials And Methods: For assessment of Vβ usage, cytotoxic T lymphocytes (CTLs) from four vaccinated patients were divided into specific and non-specific by epitope-specific enrichment. Vβ families were quantified in both fractions using reverse transcribed quantitative PCR. Vβ11-positive 'complementary determining region 3' (CDR3) sequences were amplified from these samples, from bone marrow samples of 17 other vaccination patients, and from peripheral blood of six healthy controls, cloned and sequenced.

Results: We observed a clear bias towards Vβ11 usage of the WT1-specific CTL populations in all four patients. The predominant CDR3β amino acid (AA) sequence of patient 1 was detected in two other patients. CDR3β loops with closely related AA sequences were only found in patient 1. There were no CDR3β AA sequences with side chains of identical chemical properties detected in any patient.

Conclusion: We provide the first data addressing TCR Vβ chain usage in WT1-specific T-cell populations after HLA A*0201-restricted single peptide vaccination. We demonstrate both shared Vβ restriction and the sharing of a TCR β transcript with proven clinical impact in one patient.

Citing Articles

Spontaneous high clonal expansion of Wilms' tumor gene 1-specific cytotoxic T-lymphocytes in patients with Wilms' tumor gene 1-expressing solid tumor.

Morimoto S, Tanaka Y, Nakata J, Fujiki F, Hasegawa K, Nakajima H Cancer Immunol Immunother. 2024; 74(1):15.

PMID: 39509060 PMC: 11543974. DOI: 10.1007/s00262-024-03862-8.

Partial recovery of disturbed V-J pairing profiles of T-cell receptor in people living with HIV receiving long-term antiretroviral therapy.

Li G, Li J, Zhang H, Zhang Y, Liu D, Hao Y Sci China Life Sci. 2020; 64(1):152-161.

PMID: 32567004 PMC: 7306449. DOI: 10.1007/s11427-020-1718-2.

Cancer testis antigen Cyclin A1 harbors several HLA-A*02:01-restricted T cell epitopes, which are presented and recognized in vivo.

Teck A, Urban S, Quass P, Nelde A, Schuster H, Letsch A Cancer Immunol Immunother. 2020; 69(7):1217-1227.

PMID: 32157447 PMC: 8222032. DOI: 10.1007/s00262-020-02519-6.

Identification of 11-2-1-1-1 T cell clone specific for WT1 peptides using high-throughput gene sequencing.

Zhang Y, Xu L, Chen S, Zha X, Wei W, Li Y Biomark Res. 2019; 7:12.

PMID: 31223481 PMC: 6570921. DOI: 10.1186/s40364-019-0163-1.

WT1 peptide vaccine in Montanide in contrast to poly ICLC, is able to induce WT1-specific immune response with TCR clonal enrichment in myeloid leukemia.

Liu H, Zha Y, Choudhury N, Malnassy G, Fulton N, Green M Exp Hematol Oncol. 2018; 7:1.

PMID: 29344432 PMC: 5765712. DOI: 10.1186/s40164-018-0093-x.

References

Vignard V, Lemercier B, Lim A, Pandolfino M, Guilloux Y, Khammari A . Adoptive transfer of tumor-reactive Melan-A-specific CTL clones in melanoma patients is followed by increased frequencies of additional Melan-A-specific T cells. J Immunol. 2005; 175(7):4797-805. DOI: 10.4049/jimmunol.175.7.4797. View

Serana F, Sottini A, Caimi L, Palermo B, Natali P, Nistico P . Identification of a public CDR3 motif and a biased utilization of T-cell receptor V beta and J beta chains in HLA-A2/Melan-A-specific T-cell clonotypes of melanoma patients. J Transl Med. 2009; 7:21. PMC: 2667493. DOI: 10.1186/1479-5876-7-21. View

Derre L, Bruyninx M, Baumgaertner P, Ferber M, Schmid D, Leimgruber A . Distinct sets of alphabeta TCRs confer similar recognition of tumor antigen NY-ESO-1157-165 by interacting with its central Met/Trp residues. Proc Natl Acad Sci U S A. 2008; 105(39):15010-5. PMC: 2567484. DOI: 10.1073/pnas.0807954105. View

Yoshinaga S, Whoriskey J, Khare S, Sarmiento U, Guo J, Horan T . T-cell co-stimulation through B7RP-1 and ICOS. Nature. 2000; 402(6763):827-32. DOI: 10.1038/45582. View

Pantaleo G, Demarest J, Soudeyns H, Graziosi C, Denis F, Adelsberger J . Major expansion of CD8+ T cells with a predominant V beta usage during the primary immune response to HIV. Nature. 1994; 370(6489):463-7. DOI: 10.1038/370463a0. View

de Souza A, Bonorino C . Tumor immunosuppressive environment: effects on tumor-specific and nontumor antigen immune responses. Expert Rev Anticancer Ther. 2009; 9(9):1317-32. DOI: 10.1586/era.09.88. View

Turner S, Kedzierska K, Komodromou H, La Gruta N, Dunstone M, Webb A . Lack of prominent peptide-major histocompatibility complex features limits repertoire diversity in virus-specific CD8+ T cell populations. Nat Immunol. 2005; 6(4):382-9. DOI: 10.1038/ni1175. View

Kjer-Nielsen L, Clements C, Brooks A, Purcell A, Fontes M, McCluskey J . The structure of HLA-B8 complexed to an immunodominant viral determinant: peptide-induced conformational changes and a mode of MHC class I dimerization. J Immunol. 2002; 169(9):5153-60. DOI: 10.4049/jimmunol.169.9.5153. View

Rezvani K, Yong A, Mielke S, Savani B, Musse L, Superata J . Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood. 2007; 111(1):236-42. PMC: 2200809. DOI: 10.1182/blood-2007-08-108241. View

10.

Lefranc M, Giudicelli V, Ginestoux C, Jabado-Michaloud J, Folch G, Bellahcene F . IMGT, the international ImMunoGeneTics information system. Nucleic Acids Res. 2008; 37(Database issue):D1006-12. PMC: 2686541. DOI: 10.1093/nar/gkn838. View

11.

Callan M, Annels N, Steven N, Tan L, Wilson J, McMichael A . T cell selection during the evolution of CD8+ T cell memory in vivo. Eur J Immunol. 1998; 28(12):4382-90. DOI: 10.1002/(SICI)1521-4141(199812)28:12<4382::AID-IMMU4382>3.0.CO;2-Z. View

12.

Ho W, Nguyen H, Wolfl M, Kuball J, Greenberg P . In vitro methods for generating CD8+ T-cell clones for immunotherapy from the naïve repertoire. J Immunol Methods. 2006; 310(1-2):40-52. DOI: 10.1016/j.jim.2005.11.023. View

13.

Keilholz U, Letsch A, Busse A, Asemissen A, Bauer S, Blau I . A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood. 2009; 113(26):6541-8. DOI: 10.1182/blood-2009-02-202598. View

14.

Venturi V, Kedzierska K, Price D, Doherty P, Douek D, Turner S . Sharing of T cell receptors in antigen-specific responses is driven by convergent recombination. Proc Natl Acad Sci U S A. 2006; 103(49):18691-6. PMC: 1693724. DOI: 10.1073/pnas.0608907103. View

15.

Lim A, Trautmann L, Peyrat M, Couedel C, Davodeau F, Romagne F . Frequent contribution of T cell clonotypes with public TCR features to the chronic response against a dominant EBV-derived epitope: application to direct detection of their molecular imprint on the human peripheral T cell repertoire. J Immunol. 2000; 165(4):2001-11. DOI: 10.4049/jimmunol.165.4.2001. View

16.

Trautmann L, Rimbert M, Echasserieau K, Saulquin X, Neveu B, Dechanet J . Selection of T cell clones expressing high-affinity public TCRs within Human cytomegalovirus-specific CD8 T cell responses. J Immunol. 2005; 175(9):6123-32. DOI: 10.4049/jimmunol.175.9.6123. View

17.

Keilholz U, Goldin-Lang P, Bechrakis N, Max N, Letsch A, Schmittel A . Quantitative detection of circulating tumor cells in cutaneous and ocular melanoma and quality assessment by real-time reverse transcriptase-polymerase chain reaction. Clin Cancer Res. 2004; 10(5):1605-12. DOI: 10.1158/1078-0432.ccr-0610-3. View

18.

Cole D, Wilson M, Rivoltini L, Custer M, Nishimura M . T-cell receptor repertoire in matched MART-1 peptide-stimulated peripheral blood lymphocytes and tumor-infiltrating lymphocytes. Cancer Res. 1997; 57(23):5320-7. View

19.

Robins H, Campregher P, Srivastava S, Wacher A, Turtle C, Kahsai O . Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells. Blood. 2009; 114(19):4099-107. PMC: 2774550. DOI: 10.1182/blood-2009-04-217604. View

20.

Sensi M, Traversari C, Radrizzani M, Salvi S, Maccalli C, Mortarini R . Cytotoxic T-lymphocyte clones from different patients display limited T-cell-receptor variable-region gene usage in HLA-A2-restricted recognition of the melanoma antigen Melan-A/MART-1. Proc Natl Acad Sci U S A. 1995; 92(12):5674-8. PMC: 41759. DOI: 10.1073/pnas.92.12.5674. View